# Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation

Study · id `cardio:ct-nct06108414` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06108414](<https://clinicaltrials.gov/study/NCT06108414>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06108414

Browse, organ or system: Heart; Brain  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 4374 participants.

## Technical summary

Registry record NCT06108414. Randomized; single masking; primary purpose treatment. Start 2024-09-01 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 4374 participants (planned count; ClinicalTrials.gov record NCT06108414, source copy `cardio:ctgov-nct06108414-2024-09-19`, retrieved 2026-10-26)
- Started: 2024-09-01 (actual) (ClinicalTrials.gov record NCT06108414, source copy `cardio:ctgov-nct06108414-2024-09-19`, retrieved 2026-10-26)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06108414, source copy `cardio:ctgov-nct06108414-2024-09-19`, retrieved 2026-10-26)
- Completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT06108414, source copy `cardio:ctgov-nct06108414-2024-09-19`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06108414, source copy `cardio:ctgov-nct06108414-2024-09-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06108414-2024-09-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation
- Condition: Atrial Fibrillation
- Condition: Anticoagulant Adverse Reaction
- Condition: Stroke
- Condition: Major Adverse Cardiac Events
- Intervention (Drug): low-dose rivaroxaban
- Intervention (Drug): Standard-dose rivaroxaban
- Lead sponsor: China National Center for Cardiovascular Diseases
- Lead sponsor class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Rivaroxaban (`cardio:rivaroxaban`)
- Registry lists this organization as the lead sponsor: China National Center for Cardiovascular Diseases (`cardio:org-china-national-center-for-cardiovascular-diseases`)

## Provenance

Content hash: b3dea0ba498c9d081e677fdc2c769f083062155e0c06f511f41dd9f422c37292
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
